AU2004283294B2 - Detection of mutations in a gene associated with resistance to viral infection, OAS1 - Google Patents

Detection of mutations in a gene associated with resistance to viral infection, OAS1 Download PDF

Info

Publication number
AU2004283294B2
AU2004283294B2 AU2004283294A AU2004283294A AU2004283294B2 AU 2004283294 B2 AU2004283294 B2 AU 2004283294B2 AU 2004283294 A AU2004283294 A AU 2004283294A AU 2004283294 A AU2004283294 A AU 2004283294A AU 2004283294 B2 AU2004283294 B2 AU 2004283294B2
Authority
AU
Australia
Prior art keywords
seq
oas
rna
infection
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283294A
Other languages
English (en)
Other versions
AU2004283294A1 (en
Inventor
Thierry Guillaudeux
Shawn P. Iadonato
Charles L. Magness
Gary Rosenberg
Christina A. Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Two LLC
Original Assignee
Kineta Two LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36591413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004283294(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kineta Two LLC filed Critical Kineta Two LLC
Publication of AU2004283294A1 publication Critical patent/AU2004283294A1/en
Application granted granted Critical
Publication of AU2004283294B2 publication Critical patent/AU2004283294B2/en
Priority to AU2011202885A priority Critical patent/AU2011202885B2/en
Assigned to KINETA TWO, LLC reassignment KINETA TWO, LLC Request for Assignment Assignors: ILLUMIGEN BIOSCIENCES, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
AU2004283294A 2003-10-23 2004-10-22 Detection of mutations in a gene associated with resistance to viral infection, OAS1 Ceased AU2004283294B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202885A AU2011202885B2 (en) 2003-10-23 2011-06-16 Detection of mutations in a gene associated with resistance to viral infection, oas1

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US51388803P 2003-10-23 2003-10-23
US60/513,888 2003-10-23
US54237304P 2004-02-06 2004-02-06
US60/542,373 2004-02-06
US55475804P 2004-03-19 2004-03-19
US60/554,758 2004-03-19
US56052404P 2004-04-08 2004-04-08
US60/560,524 2004-04-08
US57832304P 2004-06-09 2004-06-09
US60/578,323 2004-06-09
US60524304P 2004-08-26 2004-08-26
US60/605,243 2004-08-26
PCT/US2004/035284 WO2005040428A2 (en) 2003-10-23 2004-10-22 Detection of mutations in a gene associated with resistance to viral infection, oas1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202885A Division AU2011202885B2 (en) 2003-10-23 2011-06-16 Detection of mutations in a gene associated with resistance to viral infection, oas1

Publications (2)

Publication Number Publication Date
AU2004283294A1 AU2004283294A1 (en) 2005-05-06
AU2004283294B2 true AU2004283294B2 (en) 2011-03-17

Family

ID=36591413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283294A Ceased AU2004283294B2 (en) 2003-10-23 2004-10-22 Detection of mutations in a gene associated with resistance to viral infection, OAS1

Country Status (9)

Country Link
US (8) US20070154467A1 (cg-RX-API-DMAC7.html)
EP (4) EP2083089A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007529199A (cg-RX-API-DMAC7.html)
KR (1) KR20060116825A (cg-RX-API-DMAC7.html)
CN (3) CN102174538B (cg-RX-API-DMAC7.html)
AU (1) AU2004283294B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415771A (cg-RX-API-DMAC7.html)
CA (1) CA2543789A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005040428A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
WO2007061690A2 (en) 2005-11-23 2007-05-31 Illumigen Biosciences, Inc. Novel pharmaceutical compositions for the treatment of virus infection and cancer
CN101627117B (zh) * 2006-08-01 2013-10-30 奇尼塔二有限责任公司 医药制造方法
EP2207902A1 (en) * 2007-11-09 2010-07-21 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon
EP2123748A1 (en) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
CN102517338B (zh) * 2011-12-09 2014-07-23 宁夏共享集团有限责任公司 一种微生物发酵糠醛渣生产生化腐植酸的方法
US11624082B2 (en) * 2018-06-21 2023-04-11 Universiteit Utrecht Holding B.V. Method for monitoring kinase activity in a sample
CN117305441B (zh) * 2023-10-13 2025-04-08 福建农林大学 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089003A1 (en) * 2002-04-19 2003-10-30 Imperial College Innovations Limited Methods of treatment and diagnosis of patients with hepatitis c infection

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
SE428332B (sv) 1979-03-08 1983-06-20 Wallac Oy Forfarande for fluorescensspektroskopisk bestemning av biologiskt aktivt emne, sasom hapten, antikropp eller antigen
US4293652A (en) 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4863873A (en) * 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4416988A (en) 1980-12-23 1983-11-22 Harvey Rubin Detection and isolation of enkephalin mRNA using a synthetic oligodeoxynucleotide
DE3207053A1 (de) 1982-02-26 1983-09-15 Esselte Pendaflex Corp., 11530 Garden City, N.Y. Etikettiergeraet
SE8301395L (sv) 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4617261A (en) 1984-03-21 1986-10-14 Cetus Corporation Process for labeling nucleic acids and hybridization probes
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4707404A (en) 1984-04-03 1987-11-17 Mitsubishi Paper Mills, Ltd. Thermal transfer recording material
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JP2509574B2 (ja) 1985-08-15 1996-06-19 アモコ・コーポレーション 標識付けした核酸
EP0244471A4 (en) 1985-10-24 1988-01-28 Siska Diagnostics Inc NUCLEIC ACID SAMPLES MARKED WITH LANTHANIDE CHELATE.
US4946773A (en) 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4863876A (en) 1987-01-15 1989-09-05 Hevey Richard C Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
JP3019994B2 (ja) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5789214A (en) 1988-03-08 1998-08-04 Novartis Finance Corporation Method of inducing gene transcription in a plant
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
DE4039415A1 (de) 1990-02-03 1991-08-08 Boehringer Mannheim Gmbh Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
JP3234598B2 (ja) 1990-11-23 2001-12-04 プラント・ジエネテイツク・システムズ・エヌ・ベー 単子葉植物の形質転換方法
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5266459A (en) * 1992-02-24 1993-11-30 The Scripps Research Institute Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
US5593874A (en) 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5866781A (en) 1993-03-08 1999-02-02 The Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
DK0733059T3 (da) 1993-12-09 2000-10-16 Univ Jefferson Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
EP0753992A4 (en) 1994-02-18 1998-02-04 Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5514758A (en) 1994-09-30 1996-05-07 The Goodyear Tire & Rubber Company Process for making latex for high performance masking tape
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US5693512A (en) 1996-03-01 1997-12-02 The Ohio State Research Foundation Method for transforming plant tissue by sonication
CN1189562C (zh) 1996-08-02 2005-02-16 吉倪塞思技术公司 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
AU9131698A (en) 1997-09-08 1999-03-29 Princeton University Human genes regulated by human cytomegalovirus and interferon
CA2312002A1 (en) 1997-12-04 1999-06-10 Isis Pharmaceuticals Inc. Human rnase h and compositions and uses thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU3367799A (en) 1998-03-30 1999-10-18 Esa Inc. Methodology for predicting and/or diagnosing disease
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030165921A1 (en) * 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
CA2402293A1 (en) * 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001245619A1 (en) * 2000-03-09 2001-09-17 Chiron Corporation Human genes and gene expression products
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
FR2823224B1 (fr) * 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
AU2002341207A1 (en) 2001-05-08 2002-11-18 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
DE10122206A1 (de) 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
US7354908B2 (en) * 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
WO2004044124A2 (en) * 2002-05-17 2004-05-27 Baylor College Of Medicine Identification of oligoadenylate synthetase-like genes
WO2004000998A2 (en) * 2002-06-19 2003-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for viral resistance genes
BR0311527A (pt) 2002-06-20 2005-02-22 Unilever Nv Processo para preparação de composição detergente sólida não-granular com bolhas de gás aprisionadas
NZ591879A (en) 2003-10-23 2012-11-30 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
DE102006036763A1 (de) 2006-08-05 2008-02-07 Khs Ag Vorrichtung und Verfahren zur Sterilisation von Behältern

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089003A1 (en) * 2002-04-19 2003-10-30 Imperial College Innovations Limited Methods of treatment and diagnosis of patients with hepatitis c infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GenBank Accession No. AC004551, 11 April 1998 *
Hitman G.A. et al. Immunogenetics, 1989, vol. 30, no. 6, pp. 427-431 *
Knapp S. et al. Genes & Immunity, 2003, vol. 4, no. 6, pp. 411-419 *

Also Published As

Publication number Publication date
AU2004283294A1 (en) 2005-05-06
EP2267154A1 (en) 2010-12-29
CN1910293B (zh) 2011-04-13
US20090123472A1 (en) 2009-05-14
US20070154467A1 (en) 2007-07-05
CA2543789A1 (en) 2005-05-06
CN102174538B (zh) 2013-06-19
US20140010800A1 (en) 2014-01-09
US8088907B2 (en) 2012-01-03
CN102174538A (zh) 2011-09-07
EP2305798A2 (en) 2011-04-06
US20120321608A1 (en) 2012-12-20
US8192973B2 (en) 2012-06-05
US8551772B2 (en) 2013-10-08
WO2005040428A3 (en) 2005-09-15
BRPI0415771A (pt) 2006-12-26
KR20060116825A (ko) 2006-11-15
CN103495153A (zh) 2014-01-08
CN1910293A (zh) 2007-02-07
EP2083089A1 (en) 2009-07-29
US9090947B2 (en) 2015-07-28
EP2305798A3 (en) 2011-04-20
WO2005040428A2 (en) 2005-05-06
US20120253027A1 (en) 2012-10-04
US20110071073A1 (en) 2011-03-24
US20140037717A1 (en) 2014-02-06
EP1689888A2 (en) 2006-08-16
JP2007529199A (ja) 2007-10-25
HK1161740A1 (en) 2012-08-03
US20110237501A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
US8551772B2 (en) Detection of mutations in a gene associated with resistance to viral infection, OAS1
JP2013208117A (ja) ウイルス感染に対する抵抗性に関連する遺伝子である、oas1における変異の検出
US20070111231A1 (en) Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3
AU2013228050B2 (en) Detection of mutations in a gene associated with resistance to viral infection, oas1
US20090186028A1 (en) Detection of mutations in a gene associated with resistance to viral infection
AU2003224283A1 (en) Methods of treatment and diagnosis of patients with hepatitis c infection
US20090155234A1 (en) Detection of mutations in a gene associated with resistance to viral infection, mx1
HK1151186A (en) Oligoadenylate synthetase
TWI415944B (zh) 偵測與病毒感染抗性有關基因(oasi)中之突變之方法
MXPA06004493A (en) Detection of mutations in a gene associated with resistance to viral infection, oas1
HK1161740B (en) Detection of mutations in a gene associated with resistance to viral infection, oas1
HK1193351A (en) Detection of mutations in a gene associated with resistance to viral infection, oas1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: KINETA TWO, LLC

Free format text: FORMER OWNER WAS: ILLUMIGEN BIOSCIENCES, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired